These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Effect of intravitreal bevacizumab on serum, aqueous, and vitreous humor levels of erythropoietin in patients with proliferative diabetic retinopathy. Cancarini A; Costagliola C; Dell'omo R; Romano M; Morescalchi F; Agnifili L; Ruggeri G; Semeraro F Minerva Endocrinol; 2014 Dec; 39(4):305-11. PubMed ID: 25371057 [TBL] [Abstract][Full Text] [Related]
23. [Introduction to the topic: anti-VEGF therapy in the management of AMD]. Meyer CH Ophthalmologe; 2008 Feb; 105(2):123-4. PubMed ID: 18256843 [No Abstract] [Full Text] [Related]
24. [Anti-VEGF inhibitors and their role in the treatment of diabetic macular oedema]. Kakkassery V; Winterhalter S; Joussen AM Klin Monbl Augenheilkd; 2010 Sep; 227(9):701-11. PubMed ID: 20845250 [TBL] [Abstract][Full Text] [Related]
27. Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy. Hattori T; Shimada H; Nakashizuka H; Mizutani Y; Mori R; Yuzawa M Retina; 2010 May; 30(5):761-4. PubMed ID: 20453802 [TBL] [Abstract][Full Text] [Related]
28. Paracentesis before intravitreal injection of bevacizumab. Tsui YP; Chiang CC; Tsai YY Can J Ophthalmol; 2008 Apr; 43(2):239; author reply 239-40. PubMed ID: 18347632 [No Abstract] [Full Text] [Related]
29. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema. Kumar V; Ghosh B; Raina UK; Goel N Acta Ophthalmol; 2010 Mar; 88(2):e3; author reply e4. PubMed ID: 19549100 [No Abstract] [Full Text] [Related]
30. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Kong L; Mintz-Hittner HA; Penland RL; Kretzer FL; Chévez-Barrios P Arch Ophthalmol; 2008 Aug; 126(8):1161-3. PubMed ID: 18695118 [No Abstract] [Full Text] [Related]
31. Treatment of exudative age-related macular degeneration: many factors to consider. Olsen TW Am J Ophthalmol; 2007 Aug; 144(2):281-3. PubMed ID: 17659955 [No Abstract] [Full Text] [Related]
32. [VEGF inhibitors in ophthalmology]. Thys J; Dupont G; Rakic JM Rev Med Liege; 2009; 64(5-6):323-6. PubMed ID: 19642468 [TBL] [Abstract][Full Text] [Related]
33. Anti-VEGF therapy: riding the wave of change. Hunyor AP Clin Exp Ophthalmol; 2008 Jul; 36(5):401-2. PubMed ID: 18925912 [No Abstract] [Full Text] [Related]
34. [Molecular targeting therapy for diabetic retinopathy]. Nakao S; Yoshida S; Enaida H; Ishibashi T Nihon Rinsho; 2012 Nov; 70 Suppl 8():628-46. PubMed ID: 23513915 [No Abstract] [Full Text] [Related]
35. The article by Kook et al 1 on the 1-year effect of bevacizumab in patients with chronic diffuse diabetic macular edema (DME). Querques G Retina; 2009 May; 29(5):718-9; author reply 719-20. PubMed ID: 19430285 [No Abstract] [Full Text] [Related]
37. Reduction in dose of intravitreous bevacizumab before vitrectomy for proliferative diabetic retinopathy. Yamaji H; Shiraga F; Shiragami C; Nomoto H; Fujita T; Fukuda K Arch Ophthalmol; 2011 Jan; 129(1):106-7. PubMed ID: 21220639 [No Abstract] [Full Text] [Related]
38. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy. Qian J; Lu Q; Tao Y; Jiang YR Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241 [TBL] [Abstract][Full Text] [Related]
39. [Results of an expert survey on VEGF inhibitors in ophthalmology]. Kühn T Klin Monbl Augenheilkd; 2011 Jul; 228(7):607-12. PubMed ID: 21472638 [TBL] [Abstract][Full Text] [Related]
40. [Bevacizumab: progress in the treatment of metastatic cancer and hope for patients with proliferative retinopathy]. Antoniak K; Nowak JZ Postepy Hig Med Dosw (Online); 2007 May; 61():320-30. PubMed ID: 17554235 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]